These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19347234)

  • 1. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection.
    De Filippis D; Steardo A; D'Amico A; Scuderi C; Cipriano M; Esposito G; Iuvone T
    ScientificWorldJournal; 2009 Mar; 9():229-35. PubMed ID: 19347234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The seek of neuroprotection: introducing cannabinoids.
    Martínez-Orgado J; Fernández-López D; Lizasoain I; Romero J
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):131-9. PubMed ID: 18221224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
    Talwar R; Potluri VK
    CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures.
    Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F
    Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid mechanisms of pain suppression.
    Walker JM; Hohmann AG
    Handb Exp Pharmacol; 2005; (168):509-54. PubMed ID: 16596786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
    Klegeris A; Bissonnette CJ; McGeer PL
    Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglial Cannabinoid CB
    Xu K; Wu Y; Tian Z; Xu Y; Wu C; Wang Z
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the cannabinoid system for pain relief?
    Chiou LC; Hu SS; Ho YC
    Acta Anaesthesiol Taiwan; 2013 Dec; 51(4):161-70. PubMed ID: 24529672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system in amyotrophic lateral sclerosis.
    Bilsland LG; Greensmith L
    Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
    De Petrocellis L; Di Marzo V
    J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for cannabinoid therapies in viral encephalitis.
    Solbrig MV; Fan Y; Hazelton P
    Brain Res; 2013 Nov; 1537():273-82. PubMed ID: 24021420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
    Croxford JL; Pryce G; Jackson SJ; Ledent C; Giovannoni G; Pertwee RG; Yamamura T; Baker D
    J Neuroimmunol; 2008 Jan; 193(1-2):120-9. PubMed ID: 18037503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic cannabinoids: analysis and metabolites.
    Elsohly MA; Gul W; Wanas AS; Radwan MM
    Life Sci; 2014 Feb; 97(1):78-90. PubMed ID: 24412391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit.
    Ganon-Elazar E; Akirav I
    Psychoneuroendocrinology; 2013 Sep; 38(9):1675-87. PubMed ID: 23433741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2.
    Arévalo-Martín A; García-Ovejero D; Rubio-Araiz A; Gómez O; Molina-Holgado F; Molina-Holgado E
    Eur J Neurosci; 2007 Sep; 26(6):1548-59. PubMed ID: 17880390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
    Gowran A; Noonan J; Campbell VA
    CNS Neurosci Ther; 2011 Dec; 17(6):637-44. PubMed ID: 20875047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance.
    Cabral GA; Marciano-Cabral F
    J Leukoc Biol; 2005 Dec; 78(6):1192-7. PubMed ID: 16204639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.